GLP-1 Market
LLY $1410.99 ▼ -0.5% NVO $40.45 ▲ +1.1% PFE $30.67 ▲ +0.5% VKTX $26.83 ▼ -1.6% KLRA $12.15 ▼ -5.5% GPCR $20.47 ▼ -6.4% RHHBY $60.68 ▼ -1.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

BGM0504 Administered

BGM0504 Administered

Company
Second Affiliated Hospital of Soochow University
Mechanism
Mechanism not yet reported
Route
Injectable
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 3, 2026

Trial details
  • Completed NCT NCT06714955

    Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

    Not yet reported BrightGene Bio-Medical Technology Co., Ltd. 30 participants Est. completion 2025-03-03 1 site Stand-alone
    Other conditions: Non-diabetic Overweight or Obese
    View official trial listing →
  • Active, not recruiting NCT NCT06716203

    A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

    Not yet reported BrightGene Bio-Medical Technology Co., Ltd. 207 participants Est. completion 2026-11-14 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT06716216

    A Study of BGM0504 in Participants With Type 2 Diabetes

    Not yet reported BrightGene Bio-Medical Technology Co., Ltd. 537 participants Est. completion 2026-11-14 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06920056

    A Study of BGM0504 in Overweight or Obese Participants

    Not yet reported BrightGene Bio-Medical Technology Co., Ltd. 28 participants Est. completion 2025-07-25 1 site Stand-alone
    Other conditions: Overweight or Obese
    View official trial listing →
  • Completed NCT NCT06973681

    A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects

    Not yet reported BrightGene Bio-Medical Technology Co., Ltd. 120 participants Est. completion 2024-09-13 1 site Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Completed NCT NCT06974825

    A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

    Not yet reported BrightGene Bio-Medical Technology Co., Ltd. 67 participants Est. completion 2024-08-13 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07064486

    A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

    Not yet reported BrightGene Bio-Medical Technology Co., Ltd. 152 participants Est. completion 2027-04-30 4 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07166081

    Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

    Not yet reported BrightGene Bio-Medical Technology Co., Ltd. 80 participants Est. completion 2026-07-15 1 site Stand-alone
    Other conditions: Non-diabetic Overweight or Obese
    View official trial listing →
  • Completed NCT NCT07836140

    A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.

    Not yet reported Second Affiliated Hospital of Soochow University 60 participants Est. completion 2026-04-30 1 site Stand-alone
    Other conditions: Obesity / Overweight
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: BGM0504 Administered, BGM0504 Administered SC

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.